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Abstract: Lytic infection of differentiated cell types with human cytomegalovirus 
(HCMV) results in the temporal expression of between 170–200 open reading frames 
(ORFs). A number of studies have demonstrated the temporal regulation of these ORFs and 
that this is orchestrated by both viral and cellular mechanisms associated with the  
co-ordinated recruitment of transcription complexes and, more recently, higher order 
chromatin structure. Importantly, HCMV, like all herpes viruses, establishes a lifelong 
latent infection of the host—one major site of latency being the undifferentiated 
haematopoietic progenitor cells resident in the bone marrow. Crucially, the establishment 
of latency is concomitant with the recruitment of cellular enzymes that promote extensive 
methylation of histones bound to the major immediate early promoter. As such, the 
repressive chromatin structure formed at the major immediate early promoter (MIEP) 
elicits inhibition of IE gene expression and is a major factor involved in maintenance of 
HCMV latency. However, it is becoming increasingly clear that a distinct subset of viral 
genes is also expressed during latency. In this review, we will discuss the mechanisms that 
control the expression of these latency-associated transcripts and illustrate that regulation 
of these latency-associated promoters is also subject to chromatin mediated regulation and 
that the instructive observations previously reported regarding the negative regulation of 
the MIEP during latency are paralleled in the regulation of latent gene expression. 
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1. Introduction 
Human cytomegalovirus (HCMV) is an opportunistic pathogen that, like all herpes viruses, can 
establish a latent infection that persists for the lifetime of the host. In healthy individuals both primary 
infection and the reactivation of latent virus rarely causes any significant clinical symptoms due to a 
robust immune response in the host [1,2]. In contrast, infection or reactivation in immuno-suppressed 
transplant patients or immune-compromised late stage AIDS sufferers represents a major source of 
morbidity and mortality [3–5]. Furthermore, HCMV infection in utero remains the leading viral cause 
of infectious congenital disease [6]. As it is now clear that a major contribution to HCMV-mediated 
disease is due to the reactivation of latent virus, [2,4,7–9] a number of laboratories have studied 
intensively the mechanisms that activate and repress viral immediate early gene expression during lytic 
and latent infection, respectively. 
2. Histones, Chromatin and Gene Expression 
The ‘histone code hypothesis’ predicts that the signature of the post-translational modifications of 
histone proteins directly impacts on the transcriptional activity of the cell [10–12]. In the broadest 
terms, a promoter can be transcriptionally active or transcriptionally silent and this is influenced 
principally by the acetylation and methylation states of its associated histones [13–15]. As such, pan 
acetylation of histones H3 and H4 is directly linked with a promoter that is capable of transcription [14]. 
In contrast, trimethlyation at lysine residues 9 and 27 on histone H3 and the subsequent recruitment of 
heterochromatin protein 1 (HP1) or polycomb proteins, respectively, is indicative of a transcriptionally 
repressed promoter [16–19]. As with all biological systems caveats do exist. For instance, histone 
methylation is not exclusively indicative of repression—dimethylation at lysine residue 4 on histone 
H3 is a marker of a promoter that has been recently active [20]. Additionally, histone phosphorylation, 
which occurs at serine (10 & 28) and threonine (11 & 29) residues in the N terminal of histone H3, has 
been linked with both transcriptional activation and repression of promoter activity depending on the 
phase of the cell cycle [21].  
The regulation of the major immediate early promoter (MIEP) during latency and reactivation has 
been the subject of a number of recent reviews and, thus, it will not be covered extensively, here. 
Suffice to say, the regulation of the MIEP during latency and reactivation exhibits many hallmarks 
associated with chromatin-mediated regulation of eukaryotic gene expression. The MIEP in latently 
infected CD34+ haematopoietic cells or circulating monocytes isolated from healthy seropositive 
donors is predominantly associated with HP1 [22]—a marker of a transcriptionally silenced promoter 
that is recruited to promoters via an interaction with histone H3 trimethylated on lysine 9 (H3K9) [19]. 
However, differentiation to a mature dendritic cell (DC) phenotype is concomitant with high levels of 
acetylation of the histones bound to the MIEP and a lack of HP1 binding [22]. Importantly, the 
differences in the pattern of the modifications of the histones bound to the MIEP in undifferentiated or 
differentiated myeloid cells correlates directly with the ability to detect of IE gene expression in these 
different cell types in healthy individuals [22–26].  
It is now well accepted that differentiation-dependent changes in the post-translational modifications 
of histones around the MIEP regulate latency-associated repression and reactivation of MIEP activity. 
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However, much less is known about viral gene expression associated with latent infection and whether 
this is also regulated by histone modifications. With the advent of more sensitive high throughput 
screening techniques, the identification of a small number of latency associated transcripts (which, in 
most cases, are also expressed during lytic infection) has been possible. These transcripts expressed 
during latent infection are from viral genes dispersed throughout the viral genome, suggesting that no 
one region is particularly ‘latently active’ but rather that latency-associated transcripts are regulated 
independently by specific promoters. 
In this short review, we will present the current status of our knowledge regarding the regulation of 
expression of the latency associated transcripts of HCMV and its relationship to post-translational 
modifications of histones.  
3. Human Cytomegalovirus Latent Gene Products 
A key biological property of all herpes viruses is their ability to undergo latent infection during 
which time only a subset of viral genes are expressed. Latent herpes simplex virus (HSV) gene 
expression is predominantly restricted to one locus—the latency associated transcript (LAT)  
region [27]. Alternate splicing generates multiple non-coding RNAs with functions ranging from  
anti-apoptosis [28], anti-sense mediated inhibition of lytic gene expression [27,29] and the generation 
of miRNAs that influence gene expression during latency [30]. In contrast, a number of patterns of 
Epstein-Barr virus (EBV) latent gene expression have been reported based on the phenotype of the 
infected lymphocyte [31]. The initial infection and transformation of a resting B cell (latency III) is 
concomitant with the expression of a number of gene products including EBNA-1, -2, 3A-C,  
EBNA-LP, LMP-1, 2A and B, as well as the untranslated EBER transcripts. It is hypothesised, based 
on studies of cell lines and the analysis of tissue ex vivo that the level of EBV latent gene expression is 
down-regulated (latency II - EBNA-1, LMP-1, LMP-2A and the EBERs) with the LMP proteins 
thought to drive the differentiation into latently infected memory B cells [32–36]. Consistent with this, 
circulating immunoblastic lymphomas (latency III) are rarely detected in vivo likely due to the robust 
immune response directed against EBV in the host promoting their elimination. Indeed, the most 
common phenotype (latency 0) is genome carriage in the absence of latent gene expression [37]—
although LMP-2A transcripts have been detected in these cells [38]. However, dividing memory B 
cells that display a latency I phenotype (EBNA-1) have also been detected in vivo [35]. 
In contrast to HSV and EBV, the analysis of latent HCMV gene expression is in its relative infancy. 
Latent transcripts arising from the major immediate early region had been identified in specific 
populations of granulocyte-macrophage progenitors by the Mocarski laboratory in the 1990s [39,40] 
and US28 transcripts were also reported in an experimentally infected THP1 leukaemia cell line [41], 
but the application of high throughput molecular approaches led to the identification of a number of 
novel latent transcripts. Microarray technology employed by the Shenk and Slobedman laboratories 
detected transcription from a number of different loci in experimentally latently infected myeloid 
progenitor cells [42,43]. Subsequent work confirmed that some of these products were also expressed 
during natural latency and included UL138 [44], UL111A [43] as well as the UL81-82 anti-sense 
transcript (UL81-82ast) [45,46]. Although it is worth noting that the latent transcriptomes reported by 
these studies are not entirely overlapping, likely due to different cell types and viral strains used in the 
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analyses. Indeed, the possible effects of using different viral strains is no better illustrated than by 
recent work showing that the expression of UL144 during latency appears to be dependent on the 
strain of virus used [47] and is discussed in more detail later.  
The selective expression of viral genes during latent infection is likely to depend on similar 
mechanisms known to modulate the MIEP during latent and lytic infection. Importantly, aberrant 
expression of viral gene products not required during latency would likely risk triggering a robust host 
immune response, from the high memory T cell population known to recognise lytic antigens in 
normal HCMV carriers, with no benefit to the virus. Consequently, tight control of viral gene 
expression during latency is likely to be of some import. Since, most of the viral genes expressed 
during lytic infection are regulated by the prodigious activity of the IE72 and IE86 proteins [48–52], a 
failure to express a number of genes during latency can likely be attributed to the lack of IE expression 
resulting from extensive silencing of the MIEP which is clearly observed in latently infected myeloid 
progenitor cells (reviewed in [53]). Clearly then, gene expression during latency must be subject to 
mechanisms of regulation which are independent of the functions of viral IE gene products. In this 
review, we will use the regulation of two gene products—UL81-82ast and UL144—to illustrate 
potential mechanisms for the control of latent gene expression by HCMV in myeloid progenitor cells.  
4. The UL81-82 Antisense Transcript—LUNA 
Of all the putative latent transcripts, the factors controlling expression of the UL81-82 antisense 
transcript (UL81-82ast) during latent and lytic infection are arguably the best understood [46,47,54]. 
UL81-82ast was identified by Bego et al. [45] whilst searching for the UL81 transcription detected in 
the previous study by Goodrum et al. [42]. Bego et al. identified RNAs spanning the UL81 region in 
naturally latent monocytes and showed that transcription of this RNA actually occurs from the 
opposite strand encoding UL81 (hence the designation UL81-82ast), giving rise to a putative 133aa 
serine rich protein called LUNA (Latency Unique Nuclear Antigen). Although there is no known 
function attributed to LUNA during natural latency, there is some recent evidence that expression of 
LUNA may impact on HCMV carriage and reactivation in vitro [55].  
Superficially, at least, the regulation of LUNA promoter activity during lytic [54] and latent [46,47] 
infection appears to be mediated by very different mechanisms. However, closer scrutiny reveals that a 
number of the key proteins involved in latent or lytic LUNA transcriptional regulation actually exhibit 
overlapping functions—this provides an interesting model for the complex regulation of herpes virus 
gene promoters during different phases of infection. 
4.1. Regulation of LUNA during Latent Infection 
After confirmation that the expression of LUNA could be detected in experimentally and naturally 
latent CD34+ cells, a very simple question was asked—is the LUNA promoter associated with histone 
proteins during latency and, if so, what post-translational modifications do these histones have? 
Chromatin Immunoprecipitation analyses of the LUNA promoter alongside the MIEP showed that the 
promoter is indeed associated with histones [46]. Furthermore, the LUNA promoter, in contrast to the 
MIEP, was associated with acetylated histones [22,46]. Thus, in the latent phase of infection, the LUNA 
promoter is associated with histone post-translational modifications that support gene expression.  
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4.2. Regulation of LUNA during Lytic Infection 
Although classified as a latent transcript, LUNA, like other latency associated transcripts, is also 
expressed during lytic infection [45]. Broadly speaking, the regulation of viral gene expression during 
lytic infection is subject to regulation by histone proteins [56–61] and, consistent with this including 
LUNA, the transfected LUNA promoter is responsive to the histone deacetylase inhibitor, Trichostatin 
A (TSA). Furthermore, increased expression of LUNA was detectable in virally infected cells 
incubated with TSA [54]. Further investigation identified that the expression of IE72 was critical for 
LUNA expression during lytic infection. Interestingly, IE72 has been hypothesised to drive early and 
late viral gene expression via the sequestration of inhibitory histone deacetylase activity [59]. 
However, unlike reported for other IE72-responsive genes LUNA gene expression in an IE72 null 
background was not rescued by TSA alone [54] suggesting that, although histone proteins may play a 
role, additional regulatory mechanisms besides IE72-mediated sequestration of histone deacetylases 
were needed for LUNA promoter activation [54]. Further work showed that activation of the LUNA 
promoter during lytic infection involved IE72 overcoming the repressive activity of the cellular 
repressor hDaxx and its binding partner, ATRX [54] (Figure 1A,B). Both hDaxx and ATRX have also 
been shown by a number of groups to exert a profound phenotype on the activity of the MIEP and 
these cellular proteins are targeted by incoming tegument protein, pp71 [60,62–65].  
These observations are consistent with the view that chromatin architecture, whilst providing the 
framework for controlling gene expression, is not the only factor involved in LUNA promoter 
regulation. Indeed, it is interesting to note that parallels occur in other herpes viruses. EBV encoded 
BNRF1 disrupts the hDaxx:ATRX interaction to relieve early gene expression from the transcriptional 
silencing imposed by this complex also [66].  
4.3. LUNA Is Regulated by the GATA Transcription Factors during Latency 
The obvious question that arises from these observations is what drives differential LUNA promoter 
activity during latent infection? During latency LUNA expression must be independent of IE72 (by 
definition) whereas LUNA gene expression during lytic infection is IE72-dependent. Clues to the 
regulation of the LUNA promoter during latency came from a bioinformatics approach identifying a 
number of putative transcription sites in the LUNA promoter, including the GATA family of 
transcription factors [47]. GATA transcription factors are expressed in the haematopoietic cell lineage 
and have differential expression profiles dependent on the cell fate [67]. GATA-2 is a transcription 
factor expressed in early myeloid progenitors and declines in levels as myeloid cells differentiate and 
is sometimes referred to as the ‘master regulator’ of haematopoietic progenitor cells [68,69]. Certainly, 
GATA-2 is essential for haematopoiesis providing credence for such a grandiose moniker [69]. 
Furthermore, a lack of GATA-2 results in a severe defect in the generation of the granulocyte/ 
macrophage progenitor population [68]—a cell type which represents an important site of HCMV 
latency in the myeloid lineage [24,39,70]. Pertinently, GATA-2, along with other family members, has 
been shown to interact with chromatin modifying enzymes [71,72]. Amongst these interaction partners 
are histone acetyltransferases (pCAF and CBP/p300) which are important for histone and non-histone 
protein acetylation, including the GATA proteins themselves [71–73]. Similarly, GATA proteins also 
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interact with histone deacetylases (HDACs) with GATA-2 interacting with HDACs-3 and -5, but not 
HDAC-1 [74] and thus, like a number of proteins, GATA-2 can promote the deacetylation as well as 
acetylation of target proteins including itself. 
Figure 1. A model for the regulation of the major immediate early promoter (MIEP) and 
Latency Unique Nuclear Antigen (LUNA) promoter during lytic and latent infection.  
(A,B) Lower levels of GATA-2 expression in permissive differentiated cell types favour 
the recruitment of ATRX/Daxx to GATA-2 binding sites in the LUNA promoter to 
establish a repressive phenotype. As the lytic infection proceeds (B), IE72 is expressed 
which sequesters ATRX/Daxx complexes thus removing them as binding competitors at 
the LUNA promoter. This potentially increased GATA-2 binding which would promote 
LUNA gene expression in differentiated cells; (C) Latency is established following the 
infection of non-permissive haematopoietic CD34+ cells. High levels of transcriptional 
repressors bind to the MIEP and promote the formation of a repressive chromatin structure 
via the recruitment of histone modifying enzymes (histone methyltransferases (HMT) and 
histone deacetylases (HDAC). The relatively lower availability of transcriptional activators 
is possibly exacerbated by the exclusion of the major MIEP transactivator, pp71, from the 
nucleus in CD34+ cells. In contrast, high levels of GATA-2 are present in CD34+ cells and 
thus promote LUNA gene expression. In lytic infection, the scales are tipped towards 
transcriptional activation of the MIEP by relatively higher levels of activators versus 
repressors and the co-operative activity of pp71.  
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Interestingly, the LUNA promoter is GATA-2 responsive in transfection assays [46,47] and we 
have observed that GATA-2 over expression can rescue LUNA gene expression in IE72 virus 
infected cells (M.R. and J.S., unpublished observations). Furthermore, a study that assessed the impact 
of HCMV latency on the expression of cellular miRNAs identified that mir92a was down-regulated in 
latently infected cells [75]. Interestingly, a target of mir92a is GATA-2 and, consistent with this, 
GATA-2 expression levels were elevated in latently infected cells [75]. Thus, at least in latency, it can 
be argued that HCMV promotes a micro-environment that supports the expression of LUNA by 
modulating the availability of the GATA-2 transcription factor. Taken together, these observations 
argue that during latency high levels of GATA-2 bind to the LUNA promoter and propagate a 
chromatin environment that is pro-transcriptional. However, during lytic infection, depletion of 
hDaxx:ATRX complex is required for LUNA gene expression to occur [54]. A pertinent question is 
why, then, does this complex not repress LUNA promoter activity in myeloid progenitors? One 
possible explanation is that there are differences in the relative balance of transcriptional activators and 
repressors which determine the activity of the LUNA promoter in different cell types. The viral MIEP 
provides a paradigm for this type of differential regulation in undifferentiated and differentiated 
myeloid cells (Figure 1). High levels of transcriptional repressors that bind the MIEP are present in 
early myeloid progenitors (Figure 1C) [22,76–80]. Furthermore, HCMV binding and entry into 
undifferentiated myeloid cells has been suggested to up-regulate transcription factors that would 
promote an environment repressive for the MIEP [81]—an event that does not occur upon infection of 
permissive fibroblasts [82]. In contrast, myeloid cell differentiation is concomitant with changes in 
both the absolute levels of repressors as well as the activation of transcriptional activators of the  
MIEP [22,83–85]. In the context of the LUNA promoter, the hDaxx:ATRX complex is likely to be 
stable in many cell types.  
However, we hypothesise that in early myeloid cells high levels of GATA-2 (which would alone act 
as positive regulator of the LUNA promoter) out-compete the repressive hDaxx:ATRX complex 
(Figure 1C). In contrast, in more differentiated cells with functional levels of repressive hDaxx:ATRX, 
but lower levels of GATA-2, this GATA-2 mediated competition of hDaxx:ATRX repression would 
not occur (Figure 1B) and hDaxx:ATRX-mediated repression would need to be overcome by e.g., IE72 
during lytic infection (Figure 1B). Consistent with this view, as stated above, over-expression of 
GATA-2 into IE72 infected fibroblasts can drive LUNA gene expression. In essence, the low levels 
of GATA-2 in more differentiated cell types that HCMV lytically infects may result in the additional 
requirement of IE72 activity against hDaxx:ATRX to promote LUNA gene expression during lytic 
infection. Provocative evidence in support of the competition hypothesis is derived from a number of 
biological properties of ATRX. Firstly the N terminal region of ATRX encodes domains that  
bind to histones—particularly methylated histone H3 on lysine 9 [86] and, thus, associates with 
heterochromatic DNA where it establishes a functional interaction with the hDaxx protein [87] to 
promote transcriptional repression. Furthermore, in addition to encoding helicase and ATPase 
functions [88], the ATRX protein contains coiled-coiled regions that allow direct binding to  
DNA—with affinity for DNA regions encoding GATA protein binding sites [89] and thus could 
provide direct competition with GATA transcription factors for DNA promoter occupancy. 
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5. TNF Receptor Superfamily Member—UL144 
The UL144 gene product was originally identified as an orthologue of the tumour necrosis factor 
receptor superfamily member, herpes virus entry mediator (HVEM) [90,91]. As such, UL144 like 
HVEM can interact with BTLA to inhibit the proliferation of activated T cells [92]. As well as this 
intercellular function, UL144 has been shown to modulate intracellular signalling to regulate further 
immune responses to infection by hijacking NF-kB signaling [93,94]. UL144 recruits cellular TRAF-6 
to promote CCL22 expression [94]—a cytokine that has been shown to promote the migration of Th2 
and T regulatory cells which could impact on immune-surveillance and clearance of infected cells by 
the Th1 T cell repertoire [95]. The activity of UL144 shares characteristics with the LMP2A gene 
product of EBV which is expressed in persistently infected B lymphocytes [32,35] and also results in 
increased CCL22 production [96]. Furthermore, although UL144 expression during latency was not 
identified in a previous study [42], the UL144-148 region of HCMV was shown to be important for 
more efficient establishment of latency in an in vitro system [44] and a subsequent re-investigation of 
UL144 expression during latent infection showed that UL144 was, indeed, expressed during HCMV 
latency [47]. 
5.1. UL144 Is Expressed during Latency in a Strain-Specific Manner 
In lytic infection, the UL144 protein is expressed with early kinetics reaching steady state levels by 
48 hours post infection [90]. Although suggestive that expression is dependent on IE gene expression 
during lytic infection, the first insights into the regulation of the UL144 promoter came from an 
analysis of different HCMV isolates during latent infection of myeloid progenitor cells and, 
interestingly, suggested some parallels to those observed with LUNA [47]. Analyses showed that 
UL144 expression did occur during latency but that this appeared to be isolate dependent [47]. 
Importantly, previous studies [42,43] that had failed to identify UL144 expression during latency were 
performed using strains of HCMV that were either UL144 deficient (AD169) or UL144 null for 
expression during latency expression (TB40/e and VR1814) - based on the these recent observations of 
Poole et al. [47]. In contrast, the HCMV sequence reference strain, Merlin [97], was UL144 positive 
for expression during latency. Thus the differences between these and previous data were easily 
reconciled and, furthermore, provided a level of cross validation for the respective studies.  
5.2. UL144 Expression during Latency Is Dependent on GATA-2 Binding Sites  
The observation by Poole et al. [47] that all the HCMV isolates analysed routinely expressed 
UL144 during lytic infection, even though this was not the case for latent infection, suggested that 
differential expression of UL144 during latency was a function of UL144 promoter activity specifically 
in myeloid progenitor cells. Sequence analysis of UL144 promoters showed that, although a high level 
of conservation was evident, a UL144 positive phenotype during latency correlated with the presence 
of putative GATA-2 binding sites in the UL144 promoter. Consistent with this, UL144 reporter 
constructs based on the Merlin Ul144 promoter were GATA-2 responsive whereas TB40/e-based 
UL144 reporter constructs were not. Additionally, the deletion of the putative GATA-2 sequences was 
sufficient to render the Merlin UL144 promoter inactive [47]. 
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Direct evidence for a physical interaction between GATA-2 and UL144 promoter correlating with 
gene expression was also obtained by performing chromatin immunoprecipitation assays on infected 
myeloid cells. Crucially, GATA-2 immuno-precipitation with the UL144 promoter was only observed 
in cells infected with strains of HCMV that supported UL144 expression [47]. Furthermore, GATA-2 
binding correlated with the detection of histone H3 di-methylated at lysine 4 bound to the UL144 
promoter. In themselves, these data argue that the UL144 promoter is regulated by post-translational 
histone modifications around the UL144 promoter during latent infection likely modulated by  
GATA-2. Pertinently, the parallels with the LUNA promoter are overt [46]. Although LUNA 
expression during latency is independent of viral strain used, the LUNA promoter binds GATA-2 and 
is also responsive to GATA-2 in transfection assays [47].  
6. Concluding Remarks 
It is becoming increasingly clear that the regulation of cytomegalovirus gene expression during all 
phases of lytic infection involves post-translational modification of histone proteins (reviewed in [98]). 
Work from a number of laboratories has now demonstrated quite clearly that extensive chromatinisation 
of HCMV genomes occur [56–58,60,61,99,100] and that, during lytic infection, at least, the virus has 
to modify chromatin to control viral gene expression [59,101]. What is now also becoming clearer is 
that a complex interplay between cellular transcription factors and higher order chromatin structure 
with viral promoters is equally as important for the latency-associated regulation of viral gene 
expression [22,46,102].  
Although the exact order of events controlling viral gene expression is still not fully understood, a 
model for the control of latent viral gene expression, based on a number of instructive observations, 
can be made. Firstly, the viral genome in the virion is naked—no histone proteins can be  
detected [56,58] consistent with a failure to detect histone proteins in purified virions by mass 
spectrometry [103]. This argues that the incoming viral genomes are subject to cellular responses that 
promote chromatinisation of the viral genome. Whether this is true for all foreign DNA is unclear but 
the association of plasmids and non-viral vector delivered DNA with histone proteins is documented  
in vitro [104] and in vivo [105]. The association of herpesvirus genomes with ND10 bodies—sites of 
extensive accumulation of histone modifying enzymes in the cell—is intrinsically repressive (reviewed 
in [106]). Indeed, the concerted attempt made by HCMV (and other herpes viruses) to disrupt these 
structures suggests they are anti-viral (reviewed in [107]). Consistent with a global repression of viral 
gene expression immediately post infection, studies of histone proteins at low MOIs show that a 
substantial number of incoming viral genomes are associated with methylated histone proteins [56]  
and that this response could be mediated by the action of a number of cellular proteins (i.e., hDaxx, 
PML and Sp100) that accumulated at ND10 bodies. Consequently, the virus, through the action of 
pp71 [62,63,65,108] and subsequently IE72 [109–112] targets these ND10 structures to quickly 
overcome repression and initiate a lytic infection, especially at high MOIs.  
During latent infection, however, it is likely that the same initial events occur—the genome is 
chromatinised immediately upon infection and that the same intrinsic immune defences are activated. 
However, the failure of pp71 to translocate to the nucleus and inactivate these defences upon infection 
of myeloid progenitors (Figure 1A) has been argued to be one possible mechanism to aid the 
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establishment of latency [113]—although whether this is mediated solely by an interaction with hDaxx 
is still not clear [114]. Regardless of the exact mechanism, there is no doubt that the failure of a major 
viral transactivator of the MIEP (pp71) to enter the nucleus would have a significant impact upon 
activation of IE gene expression. Nevertheless, there are also longstanding observations that the 
MIEP—even after transfection—is transcriptionally less active in myeloid progenitors [77,115]. The 
prevailing hypothesis is that this latent phenotype is driven by the presence of high levels of 
transcriptional repressors in myeloid progenitors, such as YY1 and ERF, promoting long term 
silencing during latency via interactions with histone deacetylase and histone methyltransferase 
enzymes (Figure 1C). However, maybe a more refined model would suggest that levels of promoter 
occupancy and the recruitment of co-factors is critical to the establishment of latency rather than the 
absolute levels of ubiquitous transcription factors. Nevertheless, it is likely that the known interactions 
of YY1 and ERF with histone deacetylases and methyltransferases contribute significantly to the 
repressive ‘chromatin phenotype’ observed in naturally latent CD34+ haematopoietic cells around the 
viral MIEP [22]. 
It is also likely that these same mechanisms which promote silencing of the MIEP in latency are 
also important for driving viral latent gene expression. GATA-2 is, like YY1 and ERF, highly 
expressed in myeloid progenitor cells [68] and, while YY1 and ERF are binding to the MIEP 
mediating repression [76,79], GATA-2 binding to the LUNA and UL144 promoters drives their 
activity [47,54]. Interestingly, an in silico analysis of the promoters of other latently expressed genes 
identified putative GATA binding sites which may be important for the expression of the vIL10 and 
UL138 gene products. It is highly likely that histones are also recruited to latent promoters 
immediately post infection and, akin to the binding of ERF and YY1 to the MIEP resulting in the 
recruitment of histone deacetylases and histone methyltransferases, it is highly plausible that the 
binding of GATA-2 to the UL144 and LUNA promoters in latently infected monocytes [47] results in 
the recruitment of, for example histone acetyltransferases, generating the histone signature we observe 
in latently infected cells [46]. This ‘open’ chromatin conformation would support transcription and is 
consistent with viral latent gene transcription observed during HCMV latency [45–47]. Clearly, it 
remains to be seen whether GATA transcription factors are solely responsible for all the latent HCMV 
transcription that has been reported. Indeed, the regulation of UL138 gene expression during latency 
has been shown to be dependent on LUNA gene expression [55] in a long term monocyte culture 
model of latency [116] by, as of yet, an unidentified mechanism. However, the expression of viral 
genes containing binding sites for transcription factors highly expressed in the myeloid progenitor cells 
is highly plausible and provides further evidence for the key role cellular mechanisms of gene 
regulation play in the control of gene expression during persistent virus infection.  
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